Additional file 1: of NLGP counterbalances the immunosuppressive effect of tumor-associated mesenchymal stem cells to restore effector T cell functions

Figure S1. Gating strategy of CD105+Vimentin+IL-10+ MSCs, as prescribed in Fig. 5b, are shown along with their respective FMO for both PBS and NLGP groups. (PNG 314 kb)